Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, m… Read more
Theralase Technologies Inc. (TLTFF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.629x
Based on the latest financial reports, Theralase Technologies Inc. (TLTFF) has a cash flow conversion efficiency ratio of -0.629x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-687.12K) by net assets ($1.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Theralase Technologies Inc. - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Theralase Technologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Theralase Technologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theralase Technologies Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Perdana Karya Perkasa Tbk
JK:PKPK
|
0.190x |
|
Dae Young Pkg
KO:014160
|
0.006x |
|
Semen Baturaja Persero Tbk
JK:SMBR
|
0.042x |
|
Pixelworks Inc
NASDAQ:PXLW
|
-0.106x |
|
Deutsche Rohstoff AG
XETRA:DR0
|
0.138x |
|
NK Co. Ltd
KO:085310
|
0.005x |
|
Test Rite International Co Ltd
TW:2908
|
0.118x |
|
FIRMA OPON.DEBICA SA ZY 8
F:FD8
|
N/A |
Annual Cash Flow Conversion Efficiency for Theralase Technologies Inc. (2012–2024)
The table below shows the annual cash flow conversion efficiency of Theralase Technologies Inc. from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.07 Million | $-3.33 Million | -1.609x | +24.73% |
| 2023-12-31 | $1.91 Million | $-4.07 Million | -2.137x | -28.78% |
| 2022-12-31 | $3.09 Million | $-5.13 Million | -1.660x | -108.79% |
| 2021-12-31 | $5.07 Million | $-4.03 Million | -0.795x | -63.83% |
| 2020-12-31 | $9.16 Million | $-4.45 Million | -0.485x | -2.38% |
| 2019-12-31 | $13.86 Million | $-6.57 Million | -0.474x | +61.07% |
| 2018-12-31 | $998.64K | $-1.22 Million | -1.217x | +41.54% |
| 2017-12-31 | $2.05 Million | $-4.26 Million | -2.082x | -142.84% |
| 2016-12-31 | $5.69 Million | $-4.88 Million | -0.858x | -7.39% |
| 2015-12-31 | $6.32 Million | $-5.04 Million | -0.799x | +27.20% |
| 2014-12-31 | $2.84 Million | $-3.12 Million | -1.097x | -111.08% |
| 2013-12-31 | $1.66 Million | $-862.92K | -0.520x | -- |
| 2012-12-31 | $-65.51K | $0.00 | 0.000x | -- |